Product Pathways - Growth Factors/Cytokines
Human Interleukin-17A (hIL-17A) #8928
|8928LF||50 µg (Carrier Free)||---||In Stock||---|
|8928LC||50 µg (With Carrier)||---||In Stock||---|
|8928SF||10 µg (Carrier Free)||---||In Stock||---|
|8928SC||10 µg (With Carrier)||---||In Stock||---|
Already purchased this product? Write a Review.
Recombinant human IL-17A (hIL-17A) Ile20-Ala155 (Accession #NP_002181) was expressed in human 293 cells at Cell Signaling Technology.
Recombinant hIL-17A contains no "tags" and the nonglycosylated protein has a calculated MW of 15,535. DTT-reduced protein migrates as a 16-24 kDa polypeptide. Heterogeneity in SDS PAGE is due to glycosylation. The non-reduced cystine-linked homodimer migrates as a 28-37 kDa protein. The expected amino-terminal IVKAG of recombinant hIL-17A was verified by amino acid sequencing.
>97% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIL-17A. All lots are greater than 97% pure
The bioactivity of recombinant hIL-17A was determined by its ability to induce IL-6 production by primary human fibroblasts. The ED50 of each lot is between 1.5 - 3.5 ng/ml.
The purity of recombinant hIL-17A was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hIL-17A and staining overnight with Coomassie Blue.
Western blot analysis of extracts from human foreskin fibroblasts untreated or treated with hIL-17A for 15 minutes, using Phospho-p38 MAPK (Thr180/Tyr182) (3D7) Rabbit mAb #9215 (upper) and p38 MAPK Antibody #9212 (lower).
The production of IL-6 by primary human fibroblasts cultured with increasing concentrations of human IL-17A was assessed. Media from cells incubated with IL-17A for 48 hours was collected and assayed for IL-6 by ELISA and the OD450 - OD650 was determined.
Less than 0.01 ng endotoxin/1 μg hIL-17A.
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hIL-17A. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.
IL-17A is a cystine-linked homodimeric pro-inflammatory cytokine produced by Th17 cells, a distinct CD4+ T cell lineage (1,2). IL-17A stimulates the production of the pro-inflammatory cytokines IL-1β, TNF-α, and IL-6. IL-17A also induces production of the neutrophil chemoattractants IL-8, CXCL1, and CXCL6 thereby bridging adaptive and innate immunity (1,2). IL-17A is intimately involved in mucosal immunity against bacterial infections (1,3) and has a putative role in some autoimmune disorders (1,4). IL-17A effects appear to be exerted primarily through binding to the IL-17RA (5). IL-17A binding induces production of cytokines, chemokines and other proteins through activation of the Erk1/2 MAP kinase, PI3K/Akt, p38, and NF-κB pathways (3,4, 6). Phosphorylation of some Jaks and Stats has been observed.
- Kolls, J.K. and Lindén, A. (2004) Immunity 21, 467-76.
- Liang, S.C. et al. (2006) J Exp Med 203, 2271-9.
- Dubin, P.J. and Kolls, J.K. (2008) Immunol Rev 226, 160-71.
- Zrioual, S. et al. (2009) J Immunol 182, 3112-20.
- Wright, J.F. et al. (2008) J Immunol 181, 2799-805.
- Rahman, M.S. et al. (2006) J Immunol 177, 4064-71.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.